TYK2 heats up with Ventyx eyeing mid-stage trials; NexImmune cites competition in pipeline cull
Ventyx said it will begin testing its TYK2 inhibitor in multiple mid-stage clinical trials before the clock strikes 2023.
The news comes just weeks before Bristol Myers Squibb is slated to find out whether it will be the first to secure a TYK2 drug approval, for its moderate to severe psoriasis asset deucravacitinib.
With positive results from a healthy volunteer study, the California biotech will soon test VTX958 in patients with psoriasis, Crohn’s disease and psoriatic arthritis. Ulcerative colitis and lupus could also be explored.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.